

23. A pharmaceutical composition comprising the antibody or antigen binding fragment of claim **1** and a pharmaceutically-acceptable carrier.

24. The pharmaceutical composition of claim **23**, wherein the antibody or antigen binding fragment is optionally conjugated to an agent selected from the group consisting of isotopes, dyes, chromagens, contrast agents, drugs, toxins, cytokines, enzymes, enzyme inhibitors, hormones, hormone antagonists, growth factors, radionuclides, metals, liposomes, nanoparticles, RNA, DNA, antioxidants, proteins, carbohydrates, lipids, chelating agents, stabilizers, or any combination thereof.

25. The pharmaceutical composition of claim **23** or **211**, wherein the antibody or antigen binding fragment is a bispecific antibody.

26. A method for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of the antibody or antigen binding fragment of the pharmaceutical composition of claim **25**.

27. (canceled)

28. (canceled)

29. (canceled)

30. A kit comprising the antibody or antigen binding fragment of claim **1** and instructions for use.

31. The kit of claim **30**, wherein the antibody or antigen binding fragment is coupled to at least one detectable label selected from the group consisting of a radioactive label, a fluorescent label, and a chromogenic label.

32. The kit of claim **30**, further comprising a secondary antibody that specifically binds to the antibody or antigen binding fragment that binds to CD3.

* * * * *